COVID-19: Kollateralschäden in der Kopf-Hals-Onkologie und Präventivmaßnahmen für künftige Pandemien

Zusammenfassung

Der Beginn der COVID-19-Pandemie führte zu enormen Herausforderungen für die globale Gesundheitsversorgung, da rasch Kapazitäten und Ressourcen für die Behandlung von COVID-19-Patienten zur Verfügung gestellt werden mussten. Dadurch kam es auch zu Einschränkungen bei der Versorgung onkologischer Patienten mit Kopf-Hals-Malignomen. Diese Übersichtsarbeit fasst die Entwicklung der Tumorinzidenzen während der Pandemie, die international erarbeiteten Richtlinien zur Versorgung von Patienten mit Kopf-Hals-Malignomen und Studien zur Verzögerung onkologischer Therapien sowie der Mortalität zusammen. Darüber hinaus werden Auswirkungen auf die psychische Gesundheit der Patienten, die psychosozialen Folgen sowie ethische Fragen beleuchtet. Perspektivisch werden Präventivmaßnahmen für derartige negative Kollateraleffekte bei künftigen Pandemien am Beispiel eines Konzepts für eine Applikationssoftware (App)-basierte digitale Betreuung von Patienten mit Kopf-Hals-Tumoren diskutiert.

Abstract

The start of the COVID-19 pandemic led to enormous challenges for global healthcare, as capacities and resources had to be made available quickly for the treatment of COVID-19 patients. As a result, restrictions had to be accepted, especially in the care of oncological patients. The collateral damage of these limitations inevitably also affects patients with head and neck cancer. This review article summarizes the development of tumor incidences during the pandemic, internationally developed guidelines for the care of patients with head and neck cancer and studies on the delay in oncological therapies and mortality. In addition, the effects on the mental health of the patients, the psychosocial consequences and ethical issues are examined. In perspective, preventive measures for such negative collateral effects in future pandemics are discussed using the example of a concept for application software (app)-based digital care for patients with head and neck cancer.

Schlüsselwörter

COVID-19-Pandemie - Kollateralschäden - Kopf-Hals-Onkologie - Therapieverzögerung - Mortalität - psychische Gesundheit - Präventivmaßnahmen - Telemedizin - digitale Lösungen - onkologische Apps

Keywords

COVID-19 pandemic - collateral damage - head and neck oncology - therapy delay - preventive measures - oncology apps

Publication History

Received: 23 May 2022

Accepted after revision: 28 December 2022

Article published online:
07 February 2023

• Literatur

• 1 Mallah SI, Ghorab OK, Al-Salmi S. et al. COVID-19: breaking down a global health crisis. Ann Clin Microbiol Antimicrob 2021; 20: 35 DOI: 10.1186/s12941-021-00438-7. (PMID: 34006330)
• 2 Akande O, Akande T. COVID-19 pandemic: A global health burden. Niger Postgrad Med J 2020; 27: 147 DOI: 10.4103/npmj.npmj_157_20. (PMID: 32687112)
• 3 Al-Quteimat OM, Amer AM. The Impact of the COVID-19 Pandemic on Cancer Patients. Am J Clin Oncol 2020; 43: 452-455 DOI: 10.1097/COC.0000000000000712. (PMID: 32304435)
• 4 Liang W, Guan W, Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335-337 DOI: 10.1016/S1470-2045(20)30096-6. (PMID: 32066541)
• 5 Liu C, Zhao Y, Okwan-Duodu D. et al. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med 2020; 17: 519-527 DOI: 10.20892/j.issn.2095-3941.2020.0289. (PMID: 32944387)
• 6 Kaufman HW, Chen Z, Niles J. et al. Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Netw Open 2020; 3: e2017267 DOI: 10.1001/jamanetworkopen.2020.17267.
• 7 Voigtländer S, Hakimhashemi A, Inwald EC. et al. Auswirkungen der COVID-19-Pandemie auf die Zahl der Krebsneuerkrankungen und Krebsbehandlungen nach Tumorstadium in Bayern. Dtsch Arztebl Int 2021; 118: 660-661 DOI: 10.3238/arztebl.m2021.0329.
• 8 Bakouny Z, Hawley JE, Choueiri TK. et al. COVID-19 and Cancer: Current Challenges and Perspectives. Cancer Cell 2020; 38: 629-646 DOI: 10.1016/j.ccell.2020.09.018. (PMID: 33049215)
• 9 Gascon L, Fournier I, Chiesa-Estomba C. et al. Systematic review of international guidelines for head and neck oncology management in COVID-19 patients. Eur Arch Otorhinolaryngol 2022; 279: 907-943 DOI: 10.1007/s00405-021-06823-4. (PMID: 33891167)
• 10 Mehanna H, Hardman JC, Shenson JA. et al. Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. Lancet Oncol 2020; 21: e350-e359 DOI: 10.1016/S1470-2045(20)30334-X.
• 11 Salari A, Jalaeefar A, Shirkhoda M. What is the best treatment option for head and neck cancers in COVID-19 pandemic? A rapid review. Am J Otolaryngol 2020; 41: 102738 DOI: 10.1016/j.amjoto.2020.102738. (PMID: 32979663)
• 12 Brody RM, Albergotti WG, Shimunov D. et al. Changes in head and neck oncologic practice during the COVID-19 pandemic. Head Neck 2020; 42: 1448-1453 DOI: 10.1002/hed.26233.
• 13 Ralli M, Colizza A, Cambria F. et al. Effects of COVID-19 pandemic on head and neck oncology activity: the experience of our University Hospital. Eur Rev Med Pharmacol Sci 2021; 25: 7268-7271 DOI: 10.26355/eurrev_202112_27419. (PMID: 34919225)
• 14 Kutikov A, Weinberg DS, Edelman MJ. et al. A War on Two Fronts: Cancer Care in the Time of COVID-19. Ann Intern Med 2020; 172: 756-758 DOI: 10.7326/M20-1133. (PMID: 32219410)
• 15 Stöver T, Dazert S, Hoffmann TK. et al. Effects of the SARS-CoV-2 pandemic on the otorhinolaryngology university hospitals in the field of medical care. Laryngorhinootologie 2020; 99: 694-706 DOI: 10.1055/a-1232-4911. (PMID: 32767296)
• 16 Riemann S, Speck I, Gerstacker K. et al. Collateral damage of the COVID-19 pandemic: an alarming decline in critical procedures in otorhinolaryngology in a German university hospital. Eur Arch Oto-Rhino-Laryngology 2021; 278: 3417-3423 DOI: 10.1007/s00405-020-06519-1. (PMID: 33320294)
• 17 Osei E, Francis R, Mohamed A. et al. Impact of COVID-19 pandemic on the oncologic care continuum: Urgent need to restore patients care to pre-COVID-19 era. J Radiother Pract 2021; 1-11 DOI: 10.1017/S1460396921000303.
• 18 Mahl C, de Melo LRS, Almeida MHA. et al. Delay in head and neck cancer care during the COVID-19 pandemic and its impact on health outcomes. Braz Oral Res 2020; 34: 1-8 DOI: 10.1590/1807-3107bor-2020.vol34.0126.
• 19 De Luca P, Bisogno A, Colacurcio V. et al. Diagnosis and treatment delay of head and neck cancers during COVID-19 era in a tertiary care academic hospital: what should we expect?. Eur Arch Oto-Rhino-Laryngology 2021; 279: 961-965 DOI: 10.1007/s00405-021-06834-1.
• 20 Metzger K, Mrosek J, Zittel S. et al. Treatment delay and tumor size in patients with oral cancer during the first year of the COVID-19 pandemic. Head Neck 2021; 43: 3493-3497 DOI: 10.1002/hed.26858.
• 21 Bucher S, Neumann AS, Meerwein CM. et al. Reduction of otorhinolaryngological consultations due to the COVID-19 lockdown and its impact on disease progression. Swiss Med Wkly 2021; 151: w30068 DOI: 10.4414/smw.2021.w30068. (PMID: 34668689)
• 22 Hanna TP, King WD, Thibodeau S. et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ 2020; 371: m4087 DOI: 10.1136/bmj.m4087. (PMID: 33148535)
• 23 Herrmann T, Jakubek A, Trott KR. The importance of the timing of a gap in radiotherapy of squamous cell carcinomas of the head and neck. Strahlenther Onkol 1994; 170: 545-549 (PMID: 7940126)
• 24 Schutte HW, den Broek GB, Steens SCA. et al. Impact of optimizing diagnostic workup and reducing the time to treatment in head and neck cancer. Cancer 2020; 126: 3982-3990 DOI: 10.1002/cncr.33037. (PMID: 32634271)
• 25 Bardet A, Fraslin AM, Marghadi J. et al. Impact of COVID-19 on healthcare organisation and cancer outcomes. Eur J Cancer 2021; 153: 123-132 DOI: 10.1016/j.ejca.2021.05.012. (PMID: 34153714)
• 26 Ng J, Stovezky YR, Brenner DJ. et al. Development of a Model to Estimate the Association Between Delay in Cancer Treatment and Local Tumor Control and Risk of Metastases. JAMA Netw open 2021; 4: e2034065 DOI: 10.1001/jamanetworkopen.2020.34065.
• 27 Bitzer EM, Ansmann L, Hörold M. et al. „… oder doch lieber daheimbleiben?“ – Unterstützung bei der Entscheidung zur Inanspruchnahme der Regelversorgung während der COVID-19-Pandemie durch Akteure des Gesundheitssystems. Bundesgesundheitsblatt – Gesundheitsforsch – Gesundheitsschutz 2021; 64: 277-284 DOI: 10.1007/s00103-021-03282-4.
• 28 Büntzel J, Walter S, Hellmund H. et al. Auswirkungen der COVID-19-Pandemie auf die Versorgung von HNO-Tumoren – die Patientenperspektive. Laryngo-Rhino-Otologie 2021; 100: 104-110 DOI: 10.1055/a-1327-4234.
• 29 Büntzel J, Klein M, Keinki C. et al. Oncology services in corona times: a flash interview among German cancer patients and their physicians. J Cancer Res Clin Oncol 2020; 146: 2713-2715 DOI: 10.1007/s00432-020-03249-z.
• 30 Büntzel J, Micke O, Klein M. et al. Take care or “German Angst”? Lessons from cancer care during COVID-19 pandemic in spring 2020. J Cancer Res Clin Oncol 2021; 147: 2093-2105 DOI: 10.1007/s00432-020-03492-4. (PMID: 33387036)
• 31 Büssing A, Recchia DR, Hübner J. et al. Tumor patients’ fears and worries and perceived changes of specific attitudes, perceptions and behaviors due to the COVID-19 pandemic are still relevant. J Cancer Res Clin Oncol 2021; 147: 1673-1683 DOI: 10.1007/s00432-021-03573-y. (PMID: 33675401)
• 32 Graboyes E, Cramer J, Balakrishnan K. et al. COVID-19 pandemic and health care disparities in head and neck cancer: Scanning the horizon. Head Neck 2020; 42: 1555-1559 DOI: 10.1002/hed.26345. (PMID: 32562325)
• 33 Gordin EA, Day A, Stankova L. et al. Care in the time of coronavirus: Ethical considerations in head and neck oncology. Head Neck 2020; 42: 1519-1525 DOI: 10.1002/hed.26272. (PMID: 32437032)
• 34 World Health Organization. Pandemic Influenza Risk Management WHO Interim Guidance. Pandemic Influ Risk Manag 2013; 1-62 https://cdn.who.int/media/docs/default-source/documents/pandamic-influenza-risk-management.pdf
• 35 Liang F, Guan P, Wu W. et al. A review of documents prepared by international organizations about influenza pandemics, including the 2009 pandemic: a bibliometric analysis. BMC Infect Dis 2018; 18: 383 DOI: 10.1186/s12879-018-3286-3.
• 36 Schmidt CO, Fluck J, Golebiewski M. et al. COVID-19-Forschungsdaten leichter zugänglich machen – Aufbau einer bundesweiten Informationsinfrastruktur. Bundesgesundheitsblatt – Gesundheitsforsch – Gesundheitsschutz 2021; 64: 1084-1092 DOI: 10.1007/s00103-021-03386-x.
• 37 Geraedts M, Eberlein-gonska M, Hecker R. et al. Empfehlungen für ein künftiges Pandemiemanagement. 2021; 118: 991-993
• 38 Buhr L, Nordmeyer E, Schicktanz Si. Pandemie-Apps: Breite Akzeptanz. Dtsch Arztebl 2021; 118: 1362-1365
• 39 Fassas S, Cummings E, Sykes KJ. et al. Telemedicine for head and neck cancer surveillance in the COVID-19 era: Promise and pitfalls. Head Neck 2021; 43: 1872-1880 DOI: 10.1002/hed.26659. (PMID: 33660409)
• 40 Layfield E, Triantafillou V, Prasad A. et al. Telemedicine for head and neck ambulatory visits during COVID-19: Evaluating usability and patient satisfaction. Head Neck 2020; 42: 1681-1689 DOI: 10.1002/hed.26285.
• 41 Prasad A, Brewster R, Newman JG. et al. Optimizing your telemedicine visit during the COVID-19 pandemic: Practice guidelines for patients with head and neck cancer. Head Neck 2020; 42: 1317-1321 DOI: 10.1002/hed.26197.
• 42 Rak K, Völker J, Taeger J. et al. Medizinische Apps in der HNO-Heilkunde. Laryngo-Rhino-Otologie 2019; 98: S253-S289 DOI: 10.1055/a-0740-4866.
• 43 Kessel KA, Vogel MM, Kessel C. et al. Mobile Health in Oncology: A Patient Survey About App-Assisted Cancer Care. JMIR mHealth uHealth 2017; 5: e81 DOI: 10.2196/mhealth.7689.
• 44 Duman-Lubberding S, van Uden-Kraan CF, Jansen F. et al. Feasibility of an eHealth application “OncoKompas” to improve personalized survivorship cancer care. Support Care Cancer 2016; 24: 2163-2171 DOI: 10.1007/s00520-015-3004-2. (PMID: 26563178)
• 45 Gomes MS, Bonan PRF, Ferreira VYN. et al. Development of a mobile application for oral cancer screening. Technol Heal Care 2017; 25: 187-195 DOI: 10.3233/THC-161259. (PMID: 27689559)
• 46 Meng L, Zhao Y, Xu X. WeChat App in the follow up of thyroid cancer patients after thyroidectomy during the COVID-19 pandemic. Br J Surg 2020; 107: e533 DOI: 10.1002/bjs.12009.
• 47 Chen ZJ, Liang WT, Liu Q. et al. Use of a Remote Oncology Pharmacy Service Platform for Patients With Cancer During the COVID-19 Pandemic: Implementation and User Acceptance Evaluation. J Med Internet Res 2021; 23: e24619 DOI: 10.2196/24619.
• 48 Basch E, Deal AM, Dueck AC. et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA – J Am Med Assoc 2017; 318: 197-198 DOI: 10.1001/jama.2017.7156.
• 49 Teckie S, Solomon J, Kadapa K. et al. A Mobile Patient-Facing App for Tracking Patient-Reported Outcomes in Head and Neck Cancer Survivors: Single-Arm Feasibility Study. JMIR Form Res 2021; 5: e24667 DOI: 10.2196/24667. (PMID: 33739291)
• 50 Sprave T, Zöller D, Stoian R. et al. App-Controlled Treatment Monitoring and Support for Head and Neck Cancer Patients (APCOT): Protocol for a Prospective Randomized Controlled Trial. JMIR Res Protoc 2020; 9: e21693 DOI: 10.2196/21693. (PMID: 33295291)
• 51 Lu DJ, Girgis M, David JM. et al. Evaluation of Mobile Health Applications to Track Patient-Reported Outcomes for Oncology Patients: A Systematic Review. Adv Radiat Oncol 2021; 6: 100576 DOI: 10.1016/j.adro.2020.09.016. (PMID: 33073061)